Incidence and risk of developing photosensitivity with targeted anticancer therapies - 12/09/19
Doi : 10.1016/j.jaad.2019.01.077
Kathryn T. Ciccolini, MSN, AGACNP-BC, OCN, DNC a, Joseph Kim, BA b, Soham P. Chaudhari, DO c, Anna Skripnik Lucas, DNP, FNP-BC, DNC, CWON-AP a, Benjamin Benhuri, MD d, Juanita Duran, MD e, Shenhong Wu, MD, PhD f, g, Mario E. Lacouture, MD a, ⁎ 
a Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York
b SUNY Downstate College of Medicine, Brooklyn, New York
c Department of Dermatology, Bay Area Corpus Christi Medical Center, Corpus Christi, Texas
d College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio
e Department of Pathology, University of Arizona, Tucson, Arizona
f Division of Hematology and Oncology, Stony Brook University Cancer Center, Stony Brook, New York
g Division of Hematology and Oncology, Department of Medicine, Northport VA Medical Center, Northport, New York
∗Reprint requests: Mario E. Lacouture, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 60th Street Outpatient Center, Ste 407, Room 4312, 16 East 60th St, New York, NY 10022Dermatology ServiceDepartment of MedicineMemorial Sloan Kettering Cancer Center60th Street Outpatient Center, Ste 407, Room 4312, 16 East 60th StNew YorkNY10022
| Funding sources: Supported in part through the National Institutes of Health, National Cancer Institute, Cancer Center Support Grant P30 CA008748. |
|
| Conflicts of interest: Dr Lacouture is a consultant and speaker for Legacy Healthcare Services, Adgero Bio Pharmaceuticals, Amryt Pharmaceuticals, Celldex Therapeutics, Debiopharm, Galderma Research and Development, Johnson and Johnson, Novocure Inc, Lindi, Merck Sharp and Dohme Corporation, Helsinn Healthcare SA, Janssen Research & Development LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim Pharma Gmbh & Co. KG, Allergan Inc, Amgen Inc, E.R. Squibb & Sons LLC, EMD Serono Inc, Astrazeneca Pharmaceuticals LP, Genentech Inc, Leo Pharma Inc, Seattle Genetics, Bayer, Manner SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality Pharmaceuticals Ltd, Novartis, and Our Brain Bank. Dr Lacouture also receives research funding from Berg, Bristol-Myers Squibb, Lutris, Paxman, Novocure, US Biotest, and Veloce. Dr Lacouture received royalties as a consultant for Takeda Milledium. Ms Ciccolini, Mr Kim, Dr Chaudhari, Dr Lucas, Dr Benhuri, Dr Duran, and Dr Wu have no conflicts of interest to disclose. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 81 - N° 4
P. 1009-1011 - octobre 2019 Retour au numéro
Article précédent
- Moonlighting policies among US dermatology residency programs: A survey
- Kishore L. Jayakumar, Jules B. Lipoff
- Determining patient preferences and willingness to pay related to scar length and appearance after skin cancer treatment on the face and trunk: A multicenter discrete choice experiment
- Nicholas Golda, William Black, Vishal Patel, Donald Neal, Jeremy Etzkorn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?